New ProteomeXchange dataset PXD041871

[ProteomeCentral Agent]

Dear ProteomeXchange subscriber, a new ProteomeXchange dataset is being announced. To see more information, click here:

https://proteomecentral.proteomexchange.org/dataset/PXD041871

Summary of dataset

Status: new
Identifier: PXD041871
Changes: 2026-03-10: Updated project metadata.
HostingRepository: PRIDE
Species: Homo sapiens
Title: Co-targeting HSP90 alpha and CDK7 overcomes resistance against HSP90 inhibitors in BCR-ABL1+ leukemia cells (Vogt et al., Cell Death Dis. 2023) and Epigenetic remodeling via HDAC6 inhibition amplifies anti-tumoral immune responses in myeloid leukemia cells (Schliehe-Diecks et al., Cell Death Dis. 2026)
Submitter: Thomas Lenz
LabHead: Kai Stühler
Description: HSP90 inhibitors (HSP90i) have not entered routinely in the clinics, primarily due to the associated resistance via heat shock response (HSR) induction and dose limiting toxicity. In this study, we employed genetic KO and knockdown (KD) models of HSP90 isoforms (α and β) for extensive multi-omics-based in vitro and in vivo characterization and identified HSP90α as the primary driver of malignancy of the two isoforms in BCR-ABL1+ leukemia cells. Notably, combinatorial ex vivo drug sensitivity screenings identified CDK7 inhibitors (CDK7i) as drugs synergizing with HSP90α inhibition.Histone deacetylase 6 (HDAC6) has emerged as a promising therapeutic target in cancer due to its immunomodulatory effects. While its prognostic significance remains debated, we demonstrate that HDAC6 loss significantly impairs myeloid leukemia progression in vivo, despite having no functional impact on leukemia cell proliferation in vitro. Global proteome and secretome profiling of HDAC6-kno
ckout (KO) cells revealed upregulation of several immune-related modulators.

HTML_URL: https://proteomecentral.proteomexchange.org/dataset/PXD041871
XML_URL: https://proteomecentral.proteomexchange.org/dataset/PXD041871&outputMode=XML

[ProteomeCentral Agent]